New Rapid Virus Counter(R) system presented at the World Vaccine Congress

BOULDER, CO–(Marketwired – March 25, 2014) – ViroCyt, LLC, the leader in rapid virus quantification, today announced the launch of the next generation Virus Counter at the World Vaccine Congress in Washington, DC. Virus Counter technology has already been adopted by leaders in viral vaccine development and therapeutic protein expression. The new system, called the Virus Counter 3100, is specifically designed for manufacturing environments and includes 21 CFR Part 11 compliant software, a 96-well compliant autosampler, and a new rugged design for use in industrial environments.

“The Virus Counter 3100 will enable our customers to extend the benefits of rapid virus quantification to their high-volume process development and manufacturing operations. “Our customers have clearly expressed their desire to move Virus Counter technology beyond their research laboratories, and ViroCyt has responded with new measures and expanded features integrated into the Virus Counter 3100,” stated Robert Kline, President and CEO of ViroCyt, LLC. “The launch of the 3100 coincides with the World Vaccine Congress, where several Virus Counter users – Sanofi Pasteur and the FDA – will speak about the value of rapid virus quantification in their organizations.”

First introduced in 2011, Virus Counter has proven to be faster, more accurate and more cost-effective than traditional virus quantification methods such as plaque titer, tissue culture infectious dose, electron microscopy and quantitative PCR. The Virus Counter delivers results in minutes rather than days or weeks, which is critical when monitoring complex and expensive virus production processes.

About ViroCyt
ViroCyt, LLC was founded with the goal of providing breakthrough solutions to the life sciences industry. Our primary focus is replacing legacy technologies that are slowing the pace of virus-related research and product development. For more information, see